Artivion (NYSE:AORT) Price Target Raised to $53.00 at Citizens Jmp

Artivion (NYSE:AORT) had its price target hoisted by Citizens Jmp from $47.00 to $53.00 in a research note released on Friday morning,Benzinga reports. The firm currently has a market outperform rating on the stock.

Several other equities analysts have also recently commented on AORT. Oppenheimer reiterated an “outperform” rating on shares of Artivion in a research note on Friday, August 8th. Needham & Company LLC increased their target price on shares of Artivion from $50.00 to $58.00 and gave the company a “buy” rating in a research note on Friday. LADENBURG THALM/SH SH downgraded Artivion from a “buy” rating to a “neutral” rating and raised their price objective for the stock from $32.00 to $38.80 in a research report on Wednesday, August 13th. JMP Securities lifted their price objective on Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a report on Friday, October 10th. Finally, Stifel Nicolaus raised their target price on Artivion from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Monday, September 29th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $49.11.

Artivion Stock Performance

Shares of Artivion stock traded down $2.68 during trading on Friday, reaching $44.82. The company’s stock had a trading volume of 582,541 shares, compared to its average volume of 433,923. Artivion has a one year low of $21.97 and a one year high of $47.69. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.48 and a current ratio of 4.78. The firm has a market cap of $2.11 billion, a price-to-earnings ratio of -106.72 and a beta of 1.65. The business’s fifty day moving average price is $42.44 and its 200-day moving average price is $35.40.

Artivion (NYSE:AORT) last released its earnings results on Thursday, November 6th. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The firm had revenue of $113.39 million for the quarter, compared to analyst estimates of $110.71 million. The business’s revenue for the quarter was up 18.9% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Artivion will post 0.37 earnings per share for the current year.

Insider Activity

In related news, CEO James P. Mackin sold 12,500 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $42.32, for a total transaction of $529,000.00. Following the completion of the sale, the chief executive officer owned 852,783 shares in the company, valued at $36,089,776.56. This trade represents a 1.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Jean F. Holloway sold 10,000 shares of Artivion stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $44.37, for a total transaction of $443,700.00. Following the transaction, the senior vice president directly owned 172,129 shares of the company’s stock, valued at $7,637,363.73. This represents a 5.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 74,858 shares of company stock worth $3,250,129 in the last quarter. 7.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Artivion

Several institutional investors have recently bought and sold shares of AORT. Principal Financial Group Inc. raised its stake in shares of Artivion by 2.4% in the first quarter. Principal Financial Group Inc. now owns 206,777 shares of the company’s stock worth $5,083,000 after acquiring an additional 4,749 shares during the last quarter. Invesco Ltd. grew its stake in shares of Artivion by 27.9% during the first quarter. Invesco Ltd. now owns 341,656 shares of the company’s stock valued at $8,398,000 after purchasing an additional 74,589 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in shares of Artivion in the second quarter valued at approximately $669,000. Fred Alger Management LLC acquired a new stake in shares of Artivion in the first quarter valued at approximately $2,969,000. Finally, Diker Management LLC bought a new position in Artivion in the 1st quarter worth approximately $369,000. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.